by Jones Day's PTAB Team | Dec 20, 2016 | Pharmaceutical, Request for Reconsideration
By Lisamarie LoGiudice, Ph.D. and Cary Miller, Ph.D. In Mylan Pharmaceuticals Inc. and Amneal Pharmaceuticals LLC v. Yeda Research & Development Co. Ltd., IPR2015-00643; -00644; -00830, the PTAB granted-in-part Patent Owner Teva’s request for rehearing of the...
by Jones Day's PTAB Team | Dec 19, 2016 | Pharmaceutical, Trial Institution
By Wanli Tang, Ph.D. and J. Patrick Elsevier, Ph.D. On December 8, 2016, the PTAB issued six institution decisions in cases IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131, and IPR2016-01132, agreeing to review claims of U.S. Patent Nos....
by Jones Day's PTAB Team | Dec 17, 2016 | Real Party in Interest
By Jaime D. Choi Ph.D. IPR petitions are required to identify “all real parties in interest,” among other things because the final written decision of the PTAB prevents the petitioner, the real party in interest, or privy of the petitioner to “request or maintain a...
by Jones Day's PTAB Team | Dec 6, 2016 | Evidentiary Issues, Final Written Decisions, Petitions
By Jennifer Chheda, Ph.D. and Cary Miller, Ph.D. On November 14, 2016, the PTAB issued a Final Written Decision upholding Paragon Bioteck, Inc.’s patent, U.S. Patent No. 8,859,623 B1 (the “’623 patent”), relating to a method of using an ophthalmic composition for...
by Jones Day's PTAB Team | Nov 14, 2016 | Federal Circuit Appeal, PTAB Trial Basics
By: Tom Ritchie The Federal Circuit vacated the Patent Trial and Appeal Board’s decision in IPR2013-508 after finding that its refusal to allow NuVasive, the patent owner, to respond to factual matters violated the Administrative Procedure Act (APA). In re: ...
